Opening the book…
After completing this chapter, you should be able to:
- Describe how discovery, nonclinical studies, clinical trials, and FDA review contribute to drug development.
- Distinguish the purposes of an IND, NDA, BLA, and ANDA.
- Compare the purposes of the three main clinical trial phases and explain how researchers protect participants.
- Explain how manufacturing controls, quality assurance, and quality control support reliable study material and commercial batches.
- Distinguish selected FDA review programs and designations from marketing approval.
- Use complaint and lot records to explain how a manufacturer investigates a problem and defines recall scope.
- Distinguish recall classes, inspection observations, warning letters, and consent decrees.
A team has found an enzyme that may help people with a rare disease. Cells in the lab respond as researchers hoped. Before the first patient receives it, the team must answer two questions. Does the evidence support testing the enzyme in people? Can the team make a supply that consistently meets its quality requirements? Years later, a pharmacist who reports particles in an approved vial depends on the same kind of careful records the team began keeping in the lab.
- 12.1: From Discovery to the Market
- This page discusses the complex and prolonged process of developing pharmaceutical products, influenced by factors like product type and disease. Development may be halted if risks surpass benefits or if manufacturing is unreliable. It distinguishes between the active pharmaceutical ingredient (API) and the final drug product. Additionally, it introduces biopharmaceuticals, which are developed using biological systems or biotechnology, including therapeutic proteins and antibodies.
- 12.2: Discovery and Nonclinical Development
- This page outlines the drug discovery and nonclinical development process, highlighting high-throughput screening (HTS) for identifying candidate compounds targeting disease mechanisms. It discusses the importance of assessing absorption, distribution, metabolism, excretion (ADME), and toxicology for safety.
- 12.3: Clinical Development and Participant Protection
- This page covers the Investigational New Drug (IND) application process, the roles of regulatory bodies such as the FDA and IRBs in clinical trials, and the significance of good clinical practice (GCP) for participant safety. It outlines the structured phases of drug testing: Phase 1 for tolerance, Phase 2 for efficacy, and Phase 3 for comprehensive safety and effectiveness data.
- 12.4: FDA Marketing Review and Other Pathways
- This page covers the regulatory processes for drug applications, specifically New Drug Applications (NDA) and Biologics License Applications (BLA) submitted to the FDA. It highlights the roles of CDER and CBER, along with pathways for biosimilars and generics through ANDAs. The page details review programs such as Priority Review and Orphan Drug Designation, including their incentives. It also discusses the Animal Rule for using animal studies in scenarios where human trials would be unethical.
- 12.5: Manufacturing Quality and Contamination Prevention
- This page highlights the significance of following U.S. current good manufacturing practice (cGMP) in pharmaceutical production to prevent contamination, which can lead to legal issues even if contaminants are not detected. It underscores the necessity of thorough cleaning, validation, and staff communication for product safety. The example of melamine contamination illustrates the importance of vigilant supply chain evaluation and raw material testing to reduce adulteration risks.
- 12.6: Postmarket Monitoring and Recall Decisions
- This page discusses postmarket surveillance for detecting safety issues not identified in clinical trials, relying on reports from various stakeholders. Elevated complaint rates trigger investigations, and effective traceability is crucial during recalls. Clear communication is vital for healthcare providers and patients, with the FDA's recall authority varying by product type. Recalls are classified into three risk-based classes, and market withdrawals address minor violations or non-violations.
- 12.7: Inspections and Enforcement
- This page discusses the FDA's authority to inspect pharmaceutical facilities for compliance with current Good Manufacturing Practices (cGMP). Inspections evaluate product quality and operational standards, potentially leading to immediate enforcement actions. Observations are recorded on Form FDA 483, which may result in warning letters for corrective actions. Responses to these observations are essential and should include investigations and preventive measures.
- 12.8: Case Study McNeil Recalls and FDA Oversight
- This page discusses McNeil's response to complaints about Tylenol Arthritis products in 2008, which led to investigations and regulatory scrutiny by 2010 due to delays in addressing quality issues. A related concern at the Fort Washington facility raised further alarms regarding pediatric products. By 2011, a federal consent decree required operational improvements.
- 12.9: Chapter Summary
- This page outlines the journey of medicine from discovery to FDA approval and oversight, stressing quality assurance and control, exemplified by the McNeil case. It introduces key terms in drug development, regulatory processes, and safety measures. Review questions and practical scenarios help readers grasp clinical research complexities, regulatory necessities, and the significance of thorough investigations and traceability in drug safety.
This page titled 12: Drug Development, Approval, and Postmarket Oversight was last modified on Thu, 05 Nov 2026 12:25:53 GMT and is shared under a CC BY-SA 4.0 license and was authored, remixed, and/or curated by Emalee MacKenzie.
The book could not be loaded just now.